56 Dean Street (56DS), a sexual health clinic in London, UK, opened in its present location in 2009. In 2015, new HIV diagnoses at 56DS peaked and began to fall; in that year the service diagnosed »25% new HIV diagnoses in men-who-have-sex-with-men (MSM) in England [1] . In this commentary we analyze new HIV diagnoses made at 56DS from 2016 to 2018.
56DS offers HIV testing irrespective of attenders' sexually transmitted infection (STI) symptomology either a third-generation test if there is no risk within the six-week window period, otherwise a fourth-generation HIV test. Patients with positive HIV serology are recalled for confirmatory testing. 56DS provides a postal home HIV sampling service: 'Dean Street at Home' before January 2018 and subsequently via Sexual Health London (SHL) [2] . Patients who test positive elsewhere such as postal tests, private clinics, GP or non-UK services may also attend for confirmatory testing.
In 2014, 56DS opened Dean Street Express (DSE), an asymptomatic STI screening service with results within 6 h [3] . Initially a walkin service, in January 2016, DSE introduced booked appointments for asymptomatic screening while preserving walk-in appointments for higher risk individuals who were identified at previous attendance and enrolled onto 'Dean Street PRIME', a web-based package of information about HIV risk reduction [1, 3, 4] . DSE was expanded further in April 2018 to provide walk-in appointments for treatment of asymptomatic STIs and contacts.
Since 2015, HIV pre-exposure prophylaxis (PrEP) monitoring at 56DS has continued to increase, initially through online pharmacies and subsequently PrEP Shop, an in-clinic pharmacy, and the PrEP IMPACT trial [5À7].
We performed a retrospective case-note review of those newly diagnosed HIV-positive at 56DS between 1st January 2016 to 31st December 2018 noting demographic data and baseline test results.
The number of HIV tests performed was obtained from clinical coding of attendances. We measured differences between groups using Mann-Whitney U test (e.g. age, CD4 count), chi-squared test (e.g. gender, place of birth) and Z-test (proportions e.g. MSM). As a service evaluation, ethics submission was not required.
Of 737 new HIV diagnoses at 56DS, 114 (15%) had the initial HIV test performed elsewhere: 43%, postal testing; 38% UK service; 11% non-UK service; 7% outreach testing.
Excluding these 114, the 623 new HIV diagnoses fell at 56DS every year over the three-year period studied: 2016 (299), 2017 (183) and 2018 (141) (Fig. 1(a) ). Most importantly, the number of HIV infections diagnosed at 56DS continues to fall suggesting the ongoing success of our combination prevention model. Most striking is the doubling in the proportion of new HIV in MSM aged 21 or under, especially as HIV tests performed in this group has also decreased. Although the actual numbers are small and not statistically significant, we wonder if HIV incidence may be increasing in this group and whether this is occurring elsewhere. If true, it is crucial that we improve access to HIV testing in younger MSM. In order to address this, we have engaged younger MSM in focus groups, and created social media content including 'Plan zero', 'Generation zero' and 'The Grass is always Grindr' [8À10].
It is possible that changes seen with time in the characteristics of those newly diagnosed with HIV may be because DSE moved from walk-in to booked appointments leading to a decrease in the frequency of HIV testing (increasing time between HIV tests) and consequent fewer acute HIV infections (lower baseline viral load, lower RITA positivity).
Moving away from walk-in appointments may also explain the fall in HIV testing in younger MSM.
HIV testing at 56DS is adapting to users' needs as demonstrated in two ways. Firstly, increasing PrEP use has led to the provision of walk-in monitoring at DSE, and consequently a recent increase in
